Unlock stock picks and a broker-level newsfeed that powers Wall Street.
OTC Markets OTCPK - Delayed Quote USD

Futura Medical plc (FAMDF)

Compare
0.1500
0.0000
(0.00%)
At close: April 1 at 4:00:00 PM EDT
Loading Chart for FAMDF
  • Previous Close 0.0000
  • Open 0.1900
  • Bid 0.0100 x --
  • Ask 0.1900 x --
  • Day's Range 0.1900 - 0.1900
  • 52 Week Range 0.0100 - 0.6000
  • Volume 500
  • Avg. Volume 17,053
  • Market Cap (intraday) 45.575M
  • Beta (5Y Monthly) 1.20
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0200
  • Earnings Date Apr 8, 2025 - Apr 14, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Futura Medical plc research, develops, and sells pharmaceutical and healthcare products for sexual health. Its lead product is Eroxon, a topical gel for the treatment of erectile dysfunction. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.

www.futuramedical.com

12

Full Time Employees

December 31

Fiscal Year Ends

Recent News: FAMDF

View More

Performance Overview: FAMDF

Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

FAMDF
60.53%
FTSE 100 (^FTSE)
5.65%

1-Year Return

FAMDF
70.00%
FTSE 100 (^FTSE)
8.58%

3-Year Return

FAMDF
53.13%
FTSE 100 (^FTSE)
14.55%

5-Year Return

FAMDF
15.38%
FTSE 100 (^FTSE)
58.30%

Compare To: FAMDF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: FAMDF

View More

Valuation Measures

Annual
As of 4/1/2025
  • Market Cap

    41.27M

  • Enterprise Value

    36.20M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.27

  • Price/Book (mrq)

    4.51

  • Enterprise Value/Revenue

    3.33

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -44.68%

  • Return on Assets (ttm)

    -26.59%

  • Return on Equity (ttm)

    -47.43%

  • Revenue (ttm)

    8.4M

  • Net Income Avi to Common (ttm)

    -3.75M

  • Diluted EPS (ttm)

    -0.0200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.92M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -3M

Research Analysis: FAMDF

View More

Company Insights: FAMDF

Research Reports: FAMDF

View More

People Also Watch